Skip to Content
Global News Select

Thermo Fisher Scientific Expects 2020 Revenue to Grow 20%

By Dave Sebastian

Thermo Fisher Scientific Inc. executives said the company expects 2020 revenue to grow 20% to about $30.52 billion, its first full-year outlook since it withdrew guidance in April due to Covid-19 uncertainty.

The scientific-equipment and diagnostics company also expects adjusted earnings to rise 48% to $18.27 a share for the year, executives said on a conference call Wednesday.

The estimates are higher than the outlook it put out in late January, when it guided for adjusted earnings of $13.49 to $13.67 a share on revenue of $26.61 billion to $27.01 billion.

The company on Wednesday posted higher-than-expected profit and sales for the September quarter as it benefited from demand for Covid-19 testing.

For the fourth quarter, the company expects organic growth of 29%, with an expected $1.75 billion in Covid-19 response revenue and organic growth in the base business of low- to mid-single digits, Finance Chief Stephen Williamson said.

The company expects fourth-quarter adjusted earnings to grow about 60% from the same quarter last year, Mr. Williamson said. He added that the outlook doesn't anticipate the kind of lockdowns seen earlier this year amid the pandemic.

Shares rose 2.4% to $476.50.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

October 21, 2020 10:28 ET (14:28 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.